Patents Granted for Mobidiag's Amplidiag® CarbaR+VRE
Based in Finland, Mobidiag Ltd is a molecular diagnostics company, have received two new patents complementing the Australian Patent n°2010247321 obtained in June 2016: US Patent n°9593381 and Japanese Patent n°6054178 covering a method and a kit for detecting antibiotic resistant bacteria, and more specifically, screening for carbapenemase genes causing carbapenem resistance in bacteria.
“At Mobidiag, we have been developing fast and reliable tests for the detection of infectious diseases, including antibiotic resistance with our Amplidiag® Carba+VRE kit and wider panels soon to come. These new additions to Mobidiag’s intellectual property are key in our global strategy and definitely strengthen our commitment towards the fight against antibiotic resistance, a major worldwide health concern nowadays” said Tuomas Tenkanen, CEO at Mobidiag.
Designed to be a cost-effective solution for high volume screening of pure culture samples, the Amplidiag® CarbaR+VRE (CE-IVD) is a multiplex PCR test that detects five major and clinically most relevant carbapenemase groups as well as two vancomycin resistance markers directly from pure cultures, with results in a few hours.
Tags: Carbapenemase Resistant Enterobacteriaceae (CRE), Vancomycin Resistant Enterococcus, Antibiotic Resistance
Date Published: March 28, 2017
Source article link: Mobidiag Oy (HQ) » company contact details
FDA-cleared Microbroth Dilution Plates for Delafloxacin and Meropenem/Vaborbactam
bioMérieux and DIAGNOSTICS IS POWER at ECCMID 2018
Check-Points Introduces the CE-IVD BD MAX™ Check-Points CPO Assay
Big Data Analytics Shows Pandemic Rise in E. coli ST1193